Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.

Coyle JT, Tsai G, Goff D.

Ann N Y Acad Sci. 2003 Nov;1003:318-27. Review.

PMID:
14684455
2.

The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.

Coyle JT, Tsai G.

Psychopharmacology (Berl). 2004 Jun;174(1):32-8. Epub 2003 Nov 25. Review.

PMID:
15205876
3.

Glutamate and schizophrenia: beyond the dopamine hypothesis.

Coyle JT.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):365-84. Epub 2006 Jun 14. Review.

PMID:
16773445
4.

Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.

Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG.

Curr Top Med Chem. 2006;6(8):771-85. Review.

PMID:
16719816
5.

Ionotropic glutamate receptors as therapeutic targets in schizophrenia.

Coyle JT, Tsai G, Goff DC.

Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):183-9. Review.

PMID:
12769626
6.

Glutamatergic mechanisms in schizophrenia.

Tsai G, Coyle JT.

Annu Rev Pharmacol Toxicol. 2002;42:165-79. Review.

PMID:
11807169
7.

Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.

Chaves C, Marque CR, Trzesniak C, Machado de Sousa JP, Zuardi AW, Crippa JA, Dursun SM, Hallak JE.

Braz J Med Biol Res. 2009 Nov;42(11):1002-14. doi: 10.1590/S0100-879X2009001100002. Review.

8.

The GABA-glutamate connection in schizophrenia: which is the proximate cause?

Coyle JT.

Biochem Pharmacol. 2004 Oct 15;68(8):1507-14. Review.

PMID:
15451393
9.

[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].

Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.

Encephale. 2001 Jan-Feb;27(1):53-9. Review. French.

PMID:
11294039
10.

N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Millan MJ.

Psychopharmacology (Berl). 2005 Apr;179(1):30-53. Epub 2005 Mar 10. Review.

PMID:
15761697
11.
12.

D-alanine added to antipsychotics for the treatment of schizophrenia.

Tsai GE, Yang P, Chang YC, Chong MY.

Biol Psychiatry. 2006 Feb 1;59(3):230-4. Epub 2005 Sep 9.

PMID:
16154544
13.

Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.

Coyle JT.

Neurotox Res. 2006 Dec;10(3-4):221-33. Review.

PMID:
17197372
14.

The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.

Labrie V, Roder JC.

Neurosci Biobehav Rev. 2010 Mar;34(3):351-72. doi: 10.1016/j.neubiorev.2009.08.002. Epub 2009 Aug 18. Review.

PMID:
19695284
15.
16.

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.

Shim SS, Hammonds MD, Kee BS.

Eur Arch Psychiatry Clin Neurosci. 2008 Feb;258(1):16-27. Epub 2007 Sep 27. Review.

PMID:
17901997
18.

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.

Mol Pharmacol. 2010 Mar;77(3):317-26. doi: 10.1124/mol.109.059865. Epub 2009 Nov 23. Review. Erratum in: Mol Pharmacol. 2010 May;77(5):884.

19.

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.

Tsai G, Lane HY, Yang P, Chong MY, Lange N.

Biol Psychiatry. 2004 Mar 1;55(5):452-6.

PMID:
15023571
20.
Items per page

Supplemental Content

Write to the Help Desk